Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have earned an average recommendation of "Buy" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $12.67.
Several equities research analysts have issued reports on the stock. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. William Blair initiated coverage on Immunic in a report on Tuesday, March 25th. They set an "outperform" rating for the company. D. Boral Capital restated a "buy" rating and issued a $17.00 price target on shares of Immunic in a research note on Wednesday, February 26th. Finally, StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th.
Check Out Our Latest Stock Analysis on Immunic
Immunic Stock Down 7.1 %
Shares of NASDAQ IMUX traded down $0.09 during mid-day trading on Friday, reaching $1.12. 642,957 shares of the company were exchanged, compared to its average volume of 604,449. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11. The stock has a market capitalization of $100.44 million, a P/E ratio of -0.91 and a beta of 1.89. The company's 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.21.
Institutional Trading of Immunic
A number of institutional investors have recently modified their holdings of the stock. Invesco Ltd. bought a new position in shares of Immunic in the fourth quarter worth $37,000. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at about $50,000. HB Wealth Management LLC acquired a new position in shares of Immunic in the 4th quarter valued at approximately $81,000. Barclays PLC acquired a new position in shares of Immunic in the 4th quarter valued at approximately $84,000. Finally, Jane Street Group LLC lifted its holdings in shares of Immunic by 121.4% during the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after acquiring an additional 38,553 shares during the period. 51.82% of the stock is currently owned by institutional investors.
About Immunic
(
Get Free ReportImmunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Further Reading
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
